Clinical trials: Cancer, Carcinoma
Hepatocellular Carcinoma
Correlation Study of Lipid Metabolites as Markers of Hepatocellular Carcinoma
As one of the common malignant tumors in China, primary liver cancer, whose incidence rate and mortality rate are always in the top five, is seriously threatening the health of people.
- Trial name
- NCT06623474
- Testing
- diagnosed by traditional diagnostic markers（such as AFP or CT etc.）
- Where
- China
- Volunteers
- 900 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Stage III Non-Small Cell Lung Cancer
Hypofractionated Intensity Modulated Chemoradiotherapy to Treat Locally Advanced Non-Small Cell Lung Cancer
Locally advanced non-small cell lung cancer can be treated successfully with chemotherapy and radiation. However, the cure rate is low.
- Trial name
- NCT00938418
- Testing
- Dose escalated, accelerated, hypofractionated radiotherapy
- Where
- 3 sites in Singapore
- Volunteers
- 43 people
- Sponsor
- National University Hospital, Singapore
Esophageal Cancer
A Prospective Study of Tumor-specific Tpex in Negative Lymph Nodes for Predicting Pathological Complete Response to Neoadjuvant PD 1 Therapy in Esophageal Cancer
The goal of this observational study is to to determine whether patients with a high proportion of precursor exhausted T cells (Tpex) in negative tumor draining lymph nodes have higher pCR.
- Trial name
- NCT07573397
- Volunteers
- 88 people
- Sponsor
- Fudan University
Esophageal Neoplasms
TQB2450 Solution for Injection (TQB2450)+Paclitaxel+Cisplatin ± Anlotinib in the Treatment of Esophageal Cancer.
The regimen of paclitaxel+cisplatin+TQB2450 injection combined or not combined with anlotinib is the first-line treatment of advanced esophageal squamous cell carcinoma.
- Trial name
- NCT05013697
- Testing
- Paclitaxel + Cisplatin + TQB2450 injection+ Anlotinib, Paclitaxel + Cisplatin + TQB2450 injection
- Where
- 5 sites in China
- Volunteers
- 48 people
- Sponsor
- Henan Cancer Hospital
Non-Small Cell Lung Cancer (NSCLC)
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
The purpose of this study is to evaluate the efficacy of Pumitamig versus Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%.
- Trial name
- NCT07361510
- Testing
- Pumitamig, Pembrolizumab
- Where
- 283 sites in United States, Argentina and 34 more
- Volunteers
- 750 people
- Sponsor
- Bristol-Myers Squibb
Liver Cancer
Sorafenib Tosylate and Chemoembolization With Doxorubicin Hydrochloride and Mitomycin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
RATIONALE: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT01011010
- Testing
- doxorubicin hydrochloride, mitomycin C, sorafenib tosylate
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
This clinical trial studies the effect of cancer directed therapy given at-home versus in the clinic for patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the…
- Conditions
- Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma, Advanced Bladder Carcinoma, Advanced Breast Carcinoma
- Trial name
- NCT05969860
- Testing
- Clinical Encounter, Home Health Encounter, Quality-of-Life Assessment
- Where
- 2 sites in United States
- Volunteers
- 220 people
- Sponsor
- Mayo Clinic
Hepatocellular Carcinoma
TACE Combined With Lenvatinib Versus TACE Sequential Lenvatinib in the Treatment of Intermediate/Advanced Liver Cancer
TACE(transcatheter arterial chemoembolization) has been recommended by domestic and international guidelines as the standard treatment for a subset of HCC patients with very high heterogeneity, including BCLC stage…
- Trial name
- NCT05220020
- Testing
- TACE(Transcatheter arterial chemoembolization), Lenvatinib
- Where
- China
- Volunteers
- 299 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma Non-resectable
DEB-TACE vs. cTACE as Conversion Therapy for Unresectable Large HCC
This study is conducted to evaluate the efficacy of drug-eluting bead transarterial chemoembolization (DEB-TACE) compared with conventional transarterial chemoembolization (cTACE) as the conversion therapy for unresectable large…
- Trial name
- NCT04967482
- Testing
- Drug-eluting bead transarterial chemoembolization (DEB-TACE), Conventional transarterial chemoembolization (cTACE)
- Where
- China
- Volunteers
- 216 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Squamous Cell Carcinoma
Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metastatic Oesophageal Squamous Cell Carcinoma
The aim of our study is to evaluate the efficacy and safety of NALIRI plus 5FU versus paclitaxel as a second-line therapy in patients with locally advanced or metastatic ESCC who had failed to cisplatin- or oxaliplatin-based…
- Trial name
- OESIRI (NCT03719924)
- Testing
- Onivyde, Paclitaxel
- Where
- 9 sites in France
- Volunteers
- 106 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
HNSCC, Head and Neck Squamous Cell Carcinoma
Single-Center Eval of Clinical & Radiological Benefit AHCC in Combo W/ SOC Tx for HPV+ Pts W/ HNSCC
This is a phase 2, single-arm, open-label clinical trial determining safety and tolerability of AHCC in subjects with HPV-positive patients with Head and Neck Squamous Cell Carcinoma.
- Trial name
- NCT06693323
- Testing
- AHCC®capsules
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of California, Irvine
Renal Clear Cell Carcinoma, Renal Papillary Cell Carcinoma
MEDI4736 Combinations in Metastatic Renal Cell Carcinoma
This study is being carried out to see if the drugs MEDI4736, Savolitinib and Tremelimumab can be used alone or in combination to reduce the size of tumours in patients with kidney cancer.
- Trial name
- CALYPSO (NCT02819596)
- Testing
- Savolitinib, MEDI4736, Tremelimumab
- Where
- United Kingdom
- Volunteers
- 69 people
- Sponsor
- Queen Mary University of London
NSCLC, EGFR
To Evaluate the Efficacy and Safety of Gefitinib in Adjuvant Chemotherapy for Lung Adenocarcinoma
The purpose of this study was to evaluate the efficacy and safety of targeted gefitinib versus oral vinorelbine and carboplatin in EGFR-mutant NSCLC patients.
- Trial name
- RCTACSCNSCLC (NCT03656393)
- Testing
- Gefitinib, Vinorelbine, Carboplatin
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Shenzhen People's Hospital
Non Small Cell Lung Cancer
Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer
This is a Phase I, open-label, 2-part study in patients with a confirmed diagnosis of epidermal growth factor receptor (EGFR) mutation positive (EGFRm+) non-small cell lung cancer (NSCLC), who have progressed following prior…
- Trial name
- NCT02317016
- Testing
- Pharmacokinetic sampling - AZD9291, AZD9291 tablet dosing, Rosuvastatin
- Where
- 13 sites in United States, France and 2 more
- Volunteers
- 44 people
- Sponsor
- AstraZeneca
Malignant Neoplasm of Breast
ICG Fluorescence Technique for the Detection of Sentinel Lymph Nodes
Objectives of Clinical Trial The main objective of this clinical trial is to show the efficacy of fluorescence lymphangiography with indocyanine green (ICG) for the detection of sentinel lymph nodes.
- Trial name
- NCT01395706
- Testing
- ICG Fluorescence technique
- Where
- Germany
- Volunteers
- 125 people
- Sponsor
- Pulsion Medical Systems SE
Cervical Cancer, Intraepithelial Neoplasia
Cervical And Self-Sample In Screening Study
The proposed study seeks to compare the diagnostic performance of Human Papillomavirus (HPV) testing in self-collected samples via the Eve Medical self-collection system© (Eve) with standard physician-collected samples for the…
- Trial name
- CASSIS (NCT02397252)
- Testing
- Eve Medical self-collection system©, cobas® PCR Female swab self-sampling, Physician-collected sampling
- Where
- Canada
- Volunteers
- 1,225 people, healthy volunteers welcome
- Sponsor
- McGill University
Hepatocellular Carcinoma
Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma
The TERTIO trial will propose to determine the clinical interest and immunological efficacy of a treatment combining the CD4 helper T-inducer cancer anti-telomerase vaccine (UCPVax) with anti-PD-L1 therapy (atezolizumab) and…
- Trial name
- TERTIO (NCT05528952)
- Testing
- Atezolizumab, Bevacizumab, UCPVax
- Where
- 14 sites in France
- Volunteers
- 105 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Head and Neck Squamous Cell Carcinoma
Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma
Two randomized trials of reirradiation after salvage surgery have been conducted by the GETTEC and GORTEC collaborative groups, both members of the French HN Intergroup: The first trial compared reirradiation and a "wait and see…
- Trial name
- ADJORL1 (NCT03406247)
- Testing
- Nivolumab, Ipilimumab
- Where
- France
- Volunteers
- 140 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Carcinoma, Non-Small-Cell Lung
Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung Cancer
Concurrent or sequential chemoradiotherapy has been recommended as the standard treatment for locally advanced and unresectable non-small cell lung cancer (NSCLC). However, its efficacy remains to be improved.
- Trial name
- NCT05306847
- Testing
- Sintilimab, Anlotinib
- Volunteers
- 93 people
- Sponsor
- Peking Union Medical College Hospital
Cancer, Non Small Cell Lung Cancer
Early Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer Patients
This exploratory clinical study is designed to obtain pre-therapeutic imaging assessments using positron emission tomography (PET) imaging in 21 patients with Stage IIIB/IV or recurrent non-small cell lung cancer (NSCLC) and an…
- Trial name
- NCT00708448
- Testing
- PET Imaging, Erlotinib, Bevacizumab
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Utah
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.